ReviewF1000Research2017
The emerging role of PET imaging in dementia.
Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review.Movement disorders clinical practice · 2026Review
- Different brain spatial metabolic patterns characterizing different subtypes of multiple system atrophy.Journal of Parkinson's disease · 2026Article
- Advanced Imaging Techniques (PET, fMRI, DTI) in Early Detection of Neurodegenerative Diseases: A Systematic Review.Health science reports · 2025Review
- High-Fat Diets in Animal Models of Alzheimer's Disease: How Can Eating Too Much Fat Increase Alzheimer's Disease Risk?Journal of Alzheimer's disease : JAD · 2024Review
- Effect of the identification group size and image resolution on the diagnostic performance of metabolic Alzheimer's disease-related pattern.EJNMMI research · 2023Article
- Clozapine induces astrocyte-dependent FDG-PET hypometabolism.European journal of nuclear medicine and molecular imaging · 2022Article
- Distinct brain dysfunctions underlying visuo-constructive deficit in DLB and AD.Brain imaging and behavior · 2022Article
- Exploring the Effect of Aliphatic Substituents on Aryl Cyano Amides on Enhancement of Fluorescence upon Binding to Amyloid-β Aggregates.ACS chemical neuroscience · 2021Article
- Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps.European journal of nuclear medicine and molecular imaging · 2021Article
- Brain Molecular Connectivity in Neurodegenerative Conditions.Brain sciences · 2021Review
- The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice.Alzheimer's research & therapy · 2021Article
- CSF p-tau/AβEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Alzheimer's Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α.Cells · 2020Review
- Imaging biomarkers in neurodegeneration: current and future practices.Alzheimer's research & therapy · 2020Review
- Brain metabolic signatures across the Alzheimer's disease spectrum.European journal of nuclear medicine and molecular imaging · 2020Article
- Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis.European journal of nuclear medicine and molecular imaging · 2019Article
- Automated synthesis of [EJNMMI radiopharmacy and chemistry · 2019Article
- Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019Article
- Screening for Dementia Caused by Modifiable Lifestyle Choices Using Hybrid PET/MRI.Journal of Alzheimer's disease reports · 2019Review
- Brain Molecular Connectivity in Neurodegenerative Diseases: Recent Advances and New Perspectives Using Positron Emission Tomography.Frontiers in neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A compelling need in the field of neurodegenerative diseases is the development and validation of biomarkers for early identification and differential diagnosis. The availability of positron emission tomography (PET) neuroimaging tools for the assessment of molecular biology and neuropathology has opened new venues in the diagnostic design and the conduction of new clinical trials. PET techniques, allowing the in vivo assessment of brain function and pathology changes, are increasingly showing great potential in supporting clinical diagnosis also in the early and even preclinical phases of dementia. This review will summarize the most recent evidence on fluorine-18 fluorodeoxyglucose-, amyloid -, tau -, and neuroinflammation - PET tools, highlighting strengths and limitations and possible new perspectives in research and clinical applications. Appropriate use of PET tools is crucial for a prompt diagnosis and target evaluation of new developed drugs aimed at slowing or preventing dementia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.